{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-162552","form_type":"8-K","ticker":"MCRB","cik":"0001609809","company_name":"Seres Therapeutics, Inc.","filed_at":"2025-07-22T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.480123+00:00","generated_at":"2026-05-18T04:18:25.412935+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Seres Therapeutics CEO Eric Shaff resigns; CFO and CLO appointed as Co-CEOs effective Aug 1, 2025","bullets":["Eric Shaff resigns as President and CEO effective July 31, 2025; remains on Board as Class I director.","Marella Thorell (EVP/CFO) and Thomas DesRosier (EVP/CLO) appointed Co-CEOs and Co-Presidents effective Aug 1, 2025.","Shaff to receive prorated 2025 bonus; Board may accelerate payment if a strategic transaction closes before year-end.","Thorell and DesRosier each receive $500,000 appointment bonus: one-third on Aug 1, 2025, balance on Jan 1, 2026 subject to retention."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-162552","json":"https://secwatch.observer/filing/0001193125-25-162552.json","markdown":"https://secwatch.observer/filing/0001193125-25-162552.md","text":"https://secwatch.observer/filing/0001193125-25-162552.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1609809/000119312525162552/0001193125-25-162552-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1609809/000119312525162552/d40383d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T04:18:25.412935+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}